Oncolytic virotherapy represents an exciting new area of cancer treatment which exploits a virus’s ability to selectively replicate and kill tumor tissue while stimulating a patient-specific immune response against cancer. Interest in the field is at an all-time high following several significant deals. However, questions still remain around delivery, product and clinical development, pre-clinical modelling, scale-up, manufacturing and suitable commercial models. CHI’s Second Annual Oncolytic Virus Immunotherapy conference brings together the leading industry and academic leaders to discuss the critical steps driving oncolytic virotherapy forward.
Venue
Sheraton Boston | Boston, MA
Event Date
-